|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Post-Stroke Spasticity | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Cerebral Infarction | |||||
| Muscle Spasticity | |||||
| Stroke | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Brain Infarction | |||||
| Brain Ischemia | |||||
| Cardiovascular Diseases | |||||
| Central Nervous System Diseases | |||||
| Cerebrovascular Disorders | |||||
| Muscle Hypertonia | |||||
| Muscular Diseases | |||||
| Musculoskeletal Diseases | |||||
| Nervous System Diseases | |||||
| Neurologic Manifestations | |||||
| Neuromuscular Manifestations | |||||
| Signs and Symptoms | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| GSK1358820 | |||||
| 5 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||